Pay in 4 interest-free payments of $6.38 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Saxenda (Liraglutide) FDA approval: 2014 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Also available as: Victoza (lower dose, approved for Type 2 diabetes) Ozempic (Semaglutide) FDA approval: 2017 for Type 2 diabetes Indicated population: Adults with Type 2 diabetes as adjunct to diet and exercise Not approved for: Weight loss (though commonly prescribed off-label) Wegovy (Semaglutide) FDA approval: 2021 for chronic weight management Indicated population: Adults with BMI 30, OR Adults with BMI 27 with at least one weight-related condition Adolescents aged 12+ with obesity Same medication as Ozempic: Different dosing and FDA indication Practical Implications The regulatory distinctions matter for: Insurance coverage: Medications are often covered only for their approved indications
Nutrition during the 2mg phase (weeks 1-4) At 2mg, appetite suppression is mild
2019 Apr;21(Suppl 2):34-42
June 2026 Update: GLP-1 Constipation Supply Status We're actively monitoring the supply of OTC osmotic laxatives and methylcellulose fibers
We will examine how each delivery method interacts with your body and what you can realistically expect from your treatment
US$ 28.45
US$ 27.82
US$ 29.17
US$ 20.22
US$ 20.11
